Compare Fidelity National Information Servcs Inc (FIS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Fidelity National Information Servcs Inc trades at $35.89 (market cap $18.15B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Fidelity National Information Servcs Inc is far larger — about 3.7× Travere Therapeutics Inc. Common Stock's market cap, and Fidelity National Information Servcs Inc pays a 5% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 89 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FIS | TVTX | |
|---|---|---|
Market Cap | $18.15B | $4.88B |
Volume | 8,219,694 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $67.94 | $67.52 |
52-Week Low | $32.44 | $26.79 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $38.66B | $5.01B |
Dividend Yield | 5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $35.47, up 3.53% with strong earnings beats in recent quarters. The stock shows bearish technical signals despite positive analyst sentiment with 57% buy ratings and a $45.50 consensus target. Fundamentals improved significantly with net income turning positive at $382 million in 2025 after prior losses, while revenue growth is projected to reach $12.2 billion in 2026. Recent business wins include core banking platform adoptions and embedded finance innovations.
FIS presents a compelling value opportunity with low P/E of 5.4 and strong profitability metrics, though technical indicators suggest near-term caution. Key risks include debt management challenges and competitive pressures in financial technology. The 27% upside to analyst targets and ongoing business momentum support a constructive outlook for patient investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
